Compare American Airlines Group Inc (AAL) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American Airlines Group Inc trades at $14.99 (market cap $10.55B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.04 (market cap $9.43B). The key difference: American Airlines Group Inc and Bio-Rad Laboratories, Inc. Class A Common Stock are close in size by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | BIO | |
|---|---|---|
Market Cap | $10.55B | $9.43B |
Sector | Industrials | Health |
52-Week High | $18.15 | $356.25 |
52-Week Low | $10.18 | $241.71 |
Enterprise Value | $38.51B | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $15.06, up 0.37% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported mixed Q2 2026 results with revenue growth but faces margin pressure from fuel costs. Analyst consensus is a Buy with a $19.63 price target, though high debt and volatile profitability remain concerns.
AAL offers potential upside from its discounted valuation and premium revenue recovery, but investors face risks from fuel price volatility, high leverage, and competitive pressures. The stock's outlook hinges on sustained travel demand and cost management amid economic uncertainty.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
